The second member, HER2, is of importance in breast cancer as overexpression or gene amplification of the HER2 oncogene is closely associated with aggressive tumour progression and poor prognosis in breast and ovarian cancer (Baselga and Cortes 2005; Baselga and Swain 2009). Here, ERBB2 is linked to ovarian carcinoma.